Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Inclusion Criteria:

Participants must have histologically confirmed unresectable stage III or stage IV cutaneous melanoma, stage IV renal cell cancer, and stage IV urothelial cancer.
ECOG performance status 0-2.
Have measurable disease per RECIST v1.1 or iRECIST. Refer to Appendix B

Have the following clinical laboratory values:

Absolute neutrophil count (ANC) ≥ 1500/ μL
Hgb ≥ 9 g/dL
Platelet count ≥ 75, 000/ μL
Total bilirubin ≤ 1.5 x ULN (upper limit of normal)
AST and ALT ≤ 2x ULN
Serum Creatinine < 2x ULN

Female participants who:

Are postmenopausal for at least 1 year before entering the screening visit, OR
Are surgically sterile, OR
Agree to practice true abstinence from heterosexual contact or agree to use effective contraception without interruption during the study therapy and 90 days after the last dose.

Male participants who:

Are surgically sterile, OR
Agree to practice true abstinence from heterosexual contact or agree to use effective contraception without interruption during the study therapy and 90 days after the last dose.

Exclusion Criteria:

Participants diagnosed with mucosal or uveal melanoma
Participants who have been treated with whole head radiation for brain metastases
Invasive cancers diagnosed < 3 years prior that required systemic treatment.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Prior anti-cancer therapy for melanoma, renal cell cancer, or urothelial cancer less than 14 days prior to first dose of study treatment.
Pregnant or nursing females
Unwilling or unable to follow protocol requirements.
Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study treatment.
Other active non-melanoma, non-renal cell, or non-urothelial metastatic cancers requiring systemic treatment.
Participants currently receiving systemic corticosteroids doses over 15mg prednisone or equivalent.
Participants with uncontrolled HIV or hepatitis.